ABSTRACT
Background Observational studies suggest that different classes of antihypertensive drugs may have different effects on the occurrence of intracranial aneurysm(IA) and subarachnoid hemorrhage(SAH). However, the reported effects in previous studies are inconsistent, and randomised data are absent. We performed a two-sample Mendelian randomization(MR) analysis to study the causal effects of genetically determined blood pressure(BP) and genetic proxies for antihypertensive drug classes on the risk of IA and SAH.
Methods Genetic instruments and outcome data were obtained from independent genome-wide association studies(GWAS) or published data, which were exclusively restricted to european ancestry. Causal relationships were identified using inverse-variance weighted MR analyses and a series of statistical sensitivity analyses. The Finngen consortium was used for repeated analysis to verify results obtained from above GWAS.
Results Two-sample MR analysis showed that genetically determined Systolic BP, Dystolic BP and Pulse Pressure were related to higher risk of IA and SAH. Based on indentified single nucleotide polymorphisms (SNPs) that influence the effect of calcium channel blockers (CCB, 43 SNPs), beta-blockers (BB, 30 SNPs), angiotensin-converting enzyme inhibitors (ACEI, 16 SNPs), angiotensin receptor blockers (ARB, 11 SNPs), and thiazides (5 SNPs), genetically determined effect of CCBs was associated with higher risk of IA (OR, 1.08 [95%CI, 1.04-1.12], P=1.21×10 -5) and SAH (OR, 1.07 [95%CI, 1.02-1.12], P=2.05×10 -3). No associations were found between other antihypertensive drugs and risk of IA or SAH. The effect of CCBs on SAH was confirmed in Finngen consortium samples(OR, 1.04 [95%CI, 1.00-1.08], P=0.042).
Conclusion This MR analysis supports the protection effect of hypertension control on the occurrence of intracranial aneurysm and subarachnoid hemorrhage. However, genetic proxies for calcium channel blockers were associated with increased risk of intracranial aneurysm and subarachnoid hemorrhage. Further studies are required to confirm these findings and investigate the underlying mechanisms.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was partially supported by grants from the National Natural Science Foundation of China (No. 81400979 and 81870931), the SanHang Program of the Naval Medical University, and the 'Climbing' program of Changhai hospital.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
None
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Non-standard Abbreviations and Acronyms
- ACEI
- angiotensin-converting enzyme inhibitor;
- ARB
- angiotensin receptor blocker;
- IA
- intracranial aneurysm;
- SAH
- subarachnoid hemorrhage;
- MR
- Mendelian randomization;
- GWAS
- genome-wide association studies;
- SNPs
- single nucleotide polymorphisms;
- BP
- blood pressure;
- CCB
- calcium channel blockers;
- BB
- beta-blockers;
- ACEI
- angiotensin-converting enzyme inhibitors;
- ARB
- angiotensin receptor blockers;
- OR
- odds ratios;
- CI
- confidence intervals;
- LD
- linkage disequilibrium;
- IVW
- inverse variance weighted;
- DBP
- diastolic blood pressure;
- SBP
- systolic blood pressure;
- PP
- pulse pressure.
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos